Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 5/20 | 0.37 |
| ▸ | MMP9 | P14780 | 5/20 | 0.37 |
| ▸ | MMP13 | P45452 | 5/20 | 0.37 |
| ▸ | ADAM17 | P78536 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2105715 | 0.90 | APP (0.40) | APPCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL2105065 | 0.80 | NPSR1 (0.33) | — | |
| SCHEMBL2770703 | 0.72 | CYP3A4 (0.42) | APPCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL8502526 | 0.70 | MMP1 (0.46) | APPMMP1MMP9MMP13ADAM17 | |
| SCHEMBL2772038 | 0.68 | GAA (0.42) | APPCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL8501551 | 0.68 | CYP3A4 (0.52) | CYP3A4CYP2C9CYP2C19MMP1MMP9 | |
| SCHEMBL3067553 | 0.67 | HPGD (0.43) | CYP2D6ALDH1A1LMNAGAAL3MBTL1 | |
| SCHEMBL8501553 | 0.67 | MMP2 (0.37) | APPCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL8498354 | 0.67 | MMP9 (0.50) | MMP1MMP9MMP13ADAM17ALDH1A1 | |
| SCHEMBL8498357 | 0.67 | MMP2 (0.37) | APPCYP3A4CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421826-B1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-8163793-B2 | Proline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | PRAP1, PRR12, SLC6A7 | APP 507/4885CYP3A4 2047/4885CYP2D6 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.